About Us

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. Our pipeline includes two clinical and one late preclinical programs in non-alcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome (PWS) and and irritable bowel syndrome (IBS). Through strategic collaborations we will deliver differentiated therapeutics to address important medical needs.